Moderna’s personalised messenger RNA (mRNA)-based cancer vaccine mRNA-4157 in combination with Merck & Co’s Keytruda was granted Priority Medicines scheme designation by the EMA on 6 April 2023.

It was also granted Breakthrough Therapy Designation by the FDA in February 2023 for the adjuvant treatment of patients with high-risk stage III/IV melanoma following complete resection based on the results of the open-label, randomised, Phase IIb KEYNOTE-942 trial.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The findings, which were presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting, held from 14-19 April, showed that mRNA-4157 in combination with Keytruda improved recurrence-free survival (RFS) compared with Keytruda alone when used as an adjuvant treatment in patients with resected high-risk melanoma, regardless of tumour mutational burden.

The overall 18-month RFS rate was 78.6% (95% confidence interval [CI], 69.0-85.6%) with the combination versus 62.2% (95% CI, 46.9-74.3%) with Keytruda alone, leading to a 44% reduction in the risk of disease recurrence or death (hazard ratio [HR], 0.561; 95% CI, 0.309-1.017; 1-sided P = 0.0266).

As part of the trial, patients’ tumour inflammation score (TIS) and PD-L1 expression were measured. By design, mRNA-4157 is made to target a patient’s unique tumour mutations, with individualised mRNA encoding for up to 34 neoantigens.

The RFS benefit with the combination versus single-agent Keytruda was observed in TIS-high tumours (HR, 0.576; 95% CI, 0.209-1.591) and TIS-non-high tumours (HR, 0.528; 95% CI, 0.253-1.101). The HR was 0.485 (95% CI, 0.226-1.039) in PD-L1 positive tumours, and was 0.162 (95% CI, 0.038-0.685) in PD-L1-negative tumours.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The positive outcome of the KEYNOTE-942 trial opens the way to personalised cancer vaccines as a new approach to improve outcomes for high-risk melanoma patients with limited treatment options. In their February press release, Moderna and Merck announced the plan to start a Phase III clinical trial of the mRNA-4157-Keytruda combination in melanoma patients in 2023.

The combinations are also under development for other oncology indications, including non-small cell lung cancer and head and neck squamous cell carcinoma, indicating the potential for a broad application of the therapy across multiple indications. In terms of the pipeline asset’s potential market opportunity, GlobalData’s Consensus Analyst Forecast database projects sales for mRNA-4157 to reach $291m by 2028.